Amgen hit with a setback as Kyprolis fails a key frontline trial for multiple myeloma
Amgen reported early Tuesday that Kyprolis has failed a Phase III trial for frontline use against multiple myeloma, a setback that can only further sharpen the disappointment analysts have felt for this therapy in light of weak sales.
Investigators say that Kyprolis combined with melphalan and prednisone essentially matched a triple combo using Takeda’s Velcade. The PFS for Kyprolis was 22.3 months compared to 22.1 months for the Velcade arm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
